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1. INTRODUCTION {#jcmm13711-sec-0001}
===============

Diabetes mellitus (DM) is one of the most serious health‐related diseases all over the world, characterized by recurrent or persistent hyperglycaemia. It was estimated that approximately 90% DM were type 2 diabetes mellitus (T2DM), which occurs due to cells developing a resistance to insulin. DM prevalence is rapidly increasing in developing countries with the development of economics. When DM was not properly managed, it can lead to life‐threatening complications,[1](#jcmm13711-bib-0001){ref-type="ref"} including diabetic macroangiopathy (hear, brain, etc.,), diabetic microangiopathy (kidney, eye, etc.,) and neuropathy. DM is an important risk factor that leads to ischaemic stroke, and DM complicated with ischaemic stroke can aggravate the mortality and morbidity of patients.[2](#jcmm13711-bib-0002){ref-type="ref"}, [3](#jcmm13711-bib-0003){ref-type="ref"} Various factors contributed to the occurrence and development of DM, such as genetic, psychological, lifestyle and environment. Among these influential factors in DM, the serum level, the activity and gene polymorphisms of paraoxonase 1 played important roles in the susceptibility of DM.

Paraoxonase 1, a member of hydrolases with a glycoprotein structure, is a 354 aa glycoprotein of about 45 kD that is synthesized in the liver, released to the blood and binds to the high‐density lipoprotein in calcium‐dependent manner.[4](#jcmm13711-bib-0004){ref-type="ref"} Paraoxonase 1 has been demonstrated approximately 200 nucleotide polymorphisms, such as Q192R polymorphism, which was significantly associated with the susceptibility to T2DM by meta‐analysis.[5](#jcmm13711-bib-0005){ref-type="ref"} Paraoxonase 1 is a multifunctional enzyme with functions of arylesterase, paraoxonase and lactonase. Serum level and activity of paraoxonase 1 are different from individuals. Paraoxonase 1 activity is affected by age, sex, lifestyle and genetic polymorphisms.

It has been reported that paraoxonase 1 activity was decreased in heart disease,[6](#jcmm13711-bib-0006){ref-type="ref"}, [7](#jcmm13711-bib-0007){ref-type="ref"} and a large number of studies have been conducted over the last two decades to demonstrate the relationship of paraoxonase 1 activity and the susceptibility to DM and DM complications. Mackness et al[8](#jcmm13711-bib-0008){ref-type="ref"} firstly found that paraoxonase 1 activity was significantly higher in diabetic population than non‐diabetic population in 1998. While, Kopprasch et al. showed no significant difference in paraoxonase 1 activity between DM and non‐DM in different population.[9](#jcmm13711-bib-0009){ref-type="ref"}, [10](#jcmm13711-bib-0010){ref-type="ref"}, [11](#jcmm13711-bib-0011){ref-type="ref"}, [12](#jcmm13711-bib-0012){ref-type="ref"}, [13](#jcmm13711-bib-0013){ref-type="ref"}, [14](#jcmm13711-bib-0014){ref-type="ref"} Meanwhile, Mackness et al[15](#jcmm13711-bib-0015){ref-type="ref"} firstly described that paraoxonase 1 activity was significantly higher in DM patients without complications than that with retinopathy in 2000. Subsequently, there were some studies on the associations between paraoxonase 1 activity and the susceptibilities of DM and DM complications. However, the previously published results remain contentious. Therefore, to firmly demonstrate the association of paraoxonase 1 activity (paraoxon as substrate) with the susceptibility to DM, diabetic macroangiopathy and diabetic microangiopathy, we performed this meta‐analysis of data from thirty‐six studies.

2. METHODS {#jcmm13711-sec-0002}
==========

We carried out literature searches in PubMed, Web of Science and China National Knowledge Internet (CNKI) without language limitation, using the following key words: "PON1" or "paraoxonase 1," "diabetes" or "diabetes mellitus" or "DM" or "T2DM" or "T1DM," and "activity." On the other hand, relevant articles were hand searched to identify additional reports.

2.1. Inclusion and exclusion criteria {#jcmm13711-sec-0003}
-------------------------------------

The following criteria were used to select articles included in this meta‐analysis: (1) published as original case‐control studies; (2) paraoxonase 1 activity was detected in serum using paraoxon as the substrate; (3) reported an association between paraoxonase 1 activity and the susceptibilities of DM, diabetic macroangiopathy and/or diabetic microangiopathy. When the same series of patients were used in more than one article, we used the latest and most complete one.

2.2. Data extraction {#jcmm13711-sec-0004}
--------------------

WDL and WCF screened all searched articles and extracted data from all eligible publications independently. For each study, we carefully extracted the following information: name of the first author, published year, country, ethnicity, type of DM, type of control and paraoxonase 1 activity (mean ± SD) in each group. If there were any discrepancies, an agreement was reached after discussion; otherwise, another author was consulted to resolve the dispute.

2.3. Statistical analysis {#jcmm13711-sec-0005}
-------------------------

Paraoxonase 1 activity in each group was described as mean ± SD. Standard mean differences (SMD) were used to evaluate the association between paraoxonase 1 activity and the susceptibilities of DM, diabetic macroangiopathy and/or diabetic microangiopathy. Heterogeneity was measured using a Chi‐square‐based *Q* test. The fixed effect model was used to calculated pooled SMD, when *I* ^2^ \< 50% and *P *\>* *.05. Otherwise, the random effect model was applied. Meta‐regression analyses on published year, ethnicity, sample size, type of control and type of DM, and subgroup analyses on type of control, ethnicity and type of DM were conducted to assess heterogeneity sources across the study. Publication bias was investigated using Egger\'s test and funnel plot. STATA 12.0 software (Stata corporation, TX, USA) was used in this meta‐analysis. *P *\<* *.05 means statistical significance.

3. RESULTS {#jcmm13711-sec-0006}
==========

3.1. Study characteristics {#jcmm13711-sec-0007}
--------------------------

Relevant publications were searched and preliminarily reviewed. As shown in Figure [1](#jcmm13711-fig-0001){ref-type="fig"}, 564 publications were identified, in which 137 duplicates and 344 irrelevant papers were excluded. Then eighty‐three citations remaining for further review. Eight original articles lacking of controls, twenty‐nine articles used other paraoxonase 1 substrates, two reviews, one performed not in serum, one with paraoxonase 1 gene polymorphism, four with other diseases or protein and one without data of paraoxonase 1 activity were all excluded. Two studies used the same case series, respectively, so the most recent publication was included.[8](#jcmm13711-bib-0008){ref-type="ref"}, [16](#jcmm13711-bib-0016){ref-type="ref"} Lastly, 36 case‐control studies were included in the meta‐analyses.[9](#jcmm13711-bib-0009){ref-type="ref"}, [10](#jcmm13711-bib-0010){ref-type="ref"}, [11](#jcmm13711-bib-0011){ref-type="ref"}, [12](#jcmm13711-bib-0012){ref-type="ref"}, [13](#jcmm13711-bib-0013){ref-type="ref"}, [14](#jcmm13711-bib-0014){ref-type="ref"}, [15](#jcmm13711-bib-0015){ref-type="ref"}, [16](#jcmm13711-bib-0016){ref-type="ref"}, [17](#jcmm13711-bib-0017){ref-type="ref"}, [18](#jcmm13711-bib-0018){ref-type="ref"}, [19](#jcmm13711-bib-0019){ref-type="ref"}, [20](#jcmm13711-bib-0020){ref-type="ref"}, [21](#jcmm13711-bib-0021){ref-type="ref"}, [22](#jcmm13711-bib-0022){ref-type="ref"}, [23](#jcmm13711-bib-0023){ref-type="ref"}, [24](#jcmm13711-bib-0024){ref-type="ref"}, [25](#jcmm13711-bib-0025){ref-type="ref"}, [26](#jcmm13711-bib-0026){ref-type="ref"}, [27](#jcmm13711-bib-0027){ref-type="ref"}, [28](#jcmm13711-bib-0028){ref-type="ref"}, [29](#jcmm13711-bib-0029){ref-type="ref"}, [30](#jcmm13711-bib-0030){ref-type="ref"}, [31](#jcmm13711-bib-0031){ref-type="ref"}, [32](#jcmm13711-bib-0032){ref-type="ref"}, [33](#jcmm13711-bib-0033){ref-type="ref"}, [34](#jcmm13711-bib-0034){ref-type="ref"}, [35](#jcmm13711-bib-0035){ref-type="ref"}, [36](#jcmm13711-bib-0036){ref-type="ref"}, [37](#jcmm13711-bib-0037){ref-type="ref"}, [38](#jcmm13711-bib-0038){ref-type="ref"}, [39](#jcmm13711-bib-0039){ref-type="ref"}, [40](#jcmm13711-bib-0040){ref-type="ref"}, [41](#jcmm13711-bib-0041){ref-type="ref"}, [42](#jcmm13711-bib-0042){ref-type="ref"}, [43](#jcmm13711-bib-0043){ref-type="ref"}, [44](#jcmm13711-bib-0044){ref-type="ref"} Thirty‐four publications were written in English, and two were written in Chinese.[17](#jcmm13711-bib-0017){ref-type="ref"}, [18](#jcmm13711-bib-0018){ref-type="ref"} The detailed information is shown in Tables [1](#jcmm13711-tbl-0001){ref-type="table"} and [2](#jcmm13711-tbl-0002){ref-type="table"}. The first author, published year, country, ethnicity, the types and numbers of cases and controls, and levels of paraoxonase 1 activity for each study were presented.

![Flow diagram of the search strategy and study selection](JCMM-22-4283-g001){#jcmm13711-fig-0001}

###### 

Characteristics of studies included in this meta‐analysis for the relationship between paraoxon activity and diabetes risk

  Author                                              Year    Type of DM   Type of control   Country          Ethnicity    Paraoxon activity (DM)                           Paraoxon activity (Control)                                                                                                                                                                     
  --------------------------------------------------- ------- ------------ ----------------- ---------------- ------------ ------------------------------------------------ ------------------------------------------------ --------------------------------------------- ----------------------------------------------- ------------------------------------------------ -----
  Inoue                                               2000    T2DM         Healthy control   Japan            Japanese     116                                              55                                               108                                           162                                             57                                               161
  Mackness                                            2002    T1DM         Healthy control   English          Englishman   178.8[b](#jcmm13711-note-0003){ref-type="fn"}    71.23[b](#jcmm13711-note-0003){ref-type="fn"}    152                                           214.6[b](#jcmm13711-note-0003){ref-type="fn"}   99.08[b](#jcmm13711-note-0003){ref-type="fn"}    282
  Letellier                                           2002    T2DM         Healthy control   France           French       217.63[b](#jcmm13711-note-0003){ref-type="fn"}   130.1[b](#jcmm13711-note-0003){ref-type="fn"}    167[b](#jcmm13711-note-0003){ref-type="fn"}   259[b](#jcmm13711-note-0003){ref-type="fn"}     154.3[b](#jcmm13711-note-0003){ref-type="fn"}    105
  Kopprasch                                           2003    T2DM         Healthy control   Finland          Caucasian    5.33                                             0.5                                              75                                            4.67                                            0.27                                             403
  Rosenblat                                           2006    NIDDM        Healthy control   Israel           Israelite    183                                              35                                               3                                             340                                             37                                               3
  Mastorikou                                          2006    T2DM         Healthy control   English          Englishman   113.6[b](#jcmm13711-note-0003){ref-type="fn"}    92.3[b](#jcmm13711-note-0003){ref-type="fn"}     36                                            269.4[b](#jcmm13711-note-0003){ref-type="fn"}   104.75[b](#jcmm13711-note-0003){ref-type="fn"}   19
  Singh                                               2007    T2DM         Healthy control   India            Indian       58.36                                            26.03                                            57                                            64.92                                           32.92                                            191
  Flekac                                              2008    T2DM         Healthy control   Czech Republic   Czech        118                                              69                                               246                                           203                                             58                                               110
  110                                                 68      86                                                                                                                                                                                                                                                                                                            
  T2DM                                                                                                                                                                                                                                                                                                                                                                      
  Unur[c](#jcmm13711-note-0004){ref-type="fn"}        2008    T2DM         Healthy control   Turkey           Turk         135.7                                            71.1                                             51                                            364.2                                           26.7                                             53
  Poh                                                 2010    T2DM         Healthy control   Malaysia         Malaysian    486.31[b](#jcmm13711-note-0003){ref-type="fn"}   284.94[b](#jcmm13711-note-0003){ref-type="fn"}   140[b](#jcmm13711-note-0003){ref-type="fn"}   581                                             315                                              153
  Abdin[c](#jcmm13711-note-0004){ref-type="fn"}       2010    T2DM         Healthy control   Egypt            Egyptian     18.79[b](#jcmm13711-note-0003){ref-type="fn"}    6.44[b](#jcmm13711-note-0003){ref-type="fn"}     40[b](#jcmm13711-note-0003){ref-type="fn"}    39.66                                           12.38                                            30
  Nowak                                               2010    T1DM         Healthy control   Poland           Polish       266.83                                           164.94                                           76                                            312.04                                          129.77                                           35
  Stefanovic                                          2010    T2DM         Healthy control   Serbia           Serbian      199.4                                            154.73                                           114                                           299.5                                           285.61                                           91
  Altuner                                             2011    T2DM         Healthy control   Turkey           Turk         80.02[b](#jcmm13711-note-0003){ref-type="fn"}    12.94[b](#jcmm13711-note-0003){ref-type="fn"}    100[b](#jcmm13711-note-0003){ref-type="fn"}   94.12                                           6.79                                             50
  Ergun                                               2011    T2DM         Healthy control   Turkey           Turk         134.67                                           66.99                                            171                                           244.45                                          114.2                                            80
  Gelisgen[c](#jcmm13711-note-0004){ref-type="fn"}    2011    GDM          Without DM        Turkey           Turk         95.31                                            18.57                                            23                                            133.15                                          18.88                                            22
  Gupta                                               2011    T2DM         Healthy control   Turkey           Turk         114.2[b](#jcmm13711-note-0003){ref-type="fn"}    47.38[b](#jcmm13711-note-0003){ref-type="fn"}    250                                           178[b](#jcmm13711-note-0003){ref-type="fn"}     63.58[b](#jcmm13711-note-0003){ref-type="fn"}    300
  Liu                                                 2011    T2DM         Healthy control   China            Chinese      142                                              55                                               100                                           222                                             99                                               50
  Tabak[c](#jcmm13711-note-0004){ref-type="fn"}       2011    T2DM         Healthy control   Turkey           Turk         113.42                                           62.38                                            69                                            260.55                                          76                                               20
  Ames                                                2012    T2DM         Healthy control   Mexico           Mexican      289.4                                            61.9                                             75                                            282.6                                           70.2                                             86
  Gbandjaba[c](#jcmm13711-note-0004){ref-type="fn"}   2012    DM           Healthy control   Morocco          Moroccan     67.83                                            89.58                                            84                                            68.91                                           99.51                                            87
  Guo                                                 2012    T2DM         Healthy control   China            Chinese      102.24[b](#jcmm13711-note-0003){ref-type="fn"}   14.95[b](#jcmm13711-note-0003){ref-type="fn"}    108[b](#jcmm13711-note-0003){ref-type="fn"}   183.52                                          49.45                                            50
  Murakami                                            2013    T2DM         Healthy control   Japan            Japanese     261                                              47                                               36                                            309                                             32                                               9
  Bansal                                              2013A   T2DM         Healthy control   India            Indian       228.34[b](#jcmm13711-note-0003){ref-type="fn"}   37.83[b](#jcmm13711-note-0003){ref-type="fn"}    157[b](#jcmm13711-note-0003){ref-type="fn"}   379[b](#jcmm13711-note-0003){ref-type="fn"}     31.5[b](#jcmm13711-note-0003){ref-type="fn"}     40
  Bansal                                              2013B   T2DM         Healthy control   India            Indian       209.7[b](#jcmm13711-note-0003){ref-type="fn"}    45.77[b](#jcmm13711-note-0003){ref-type="fn"}    265[b](#jcmm13711-note-0003){ref-type="fn"}   381[b](#jcmm13711-note-0003){ref-type="fn"}     30.33[b](#jcmm13711-note-0003){ref-type="fn"}    171
  Budak                                               2013    T2DM         Healthy control   Turkey           Turk         210.81[b](#jcmm13711-note-0003){ref-type="fn"}   46.89[b](#jcmm13711-note-0003){ref-type="fn"}    54[b](#jcmm13711-note-0003){ref-type="fn"}    258                                             60                                               24
  Helaly                                              2013    T2DM         Healthy control   Egypt            Egyptian     89.1                                             11.4                                             100                                           239.6                                           49.3                                             100
  Fekih                                               2014    T1DM         Healthy control   Tunisia          Tunisian     330                                              198                                              122                                           334                                             220                                              97
  Sreckovic                                           2014    GDM          Without DM        Austria          Austrian     35                                               9                                                9                                             75                                              18                                               11
  Craciun                                             2016    T1DM         Healthy control   Romania          Romanian     181[b](#jcmm13711-note-0003){ref-type="fn"}      38.83[b](#jcmm13711-note-0003){ref-type="fn"}    82                                            215[b](#jcmm13711-note-0003){ref-type="fn"}     83.75[b](#jcmm13711-note-0003){ref-type="fn"}    41
  Muhtaroglu                                          2016    DM           Healthy control   Turkey           Turk         73.15[b](#jcmm13711-note-0003){ref-type="fn"}    19.98[b](#jcmm13711-note-0003){ref-type="fn"}    60[b](#jcmm13711-note-0003){ref-type="fn"}    97.7[b](#jcmm13711-note-0003){ref-type="fn"}    23.175[b](#jcmm13711-note-0003){ref-type="fn"}   30
  Shakeri                                             2017    T2DM         Healthy control   Iran             Iranian      770.95                                           320.47                                           90                                            2185.64                                         428.76                                           90
  Sun                                                 2017    DM           Without DM        China            Chinese      309.4[b](#jcmm13711-note-0003){ref-type="fn"}    116.8[b](#jcmm13711-note-0003){ref-type="fn"}    51                                            366.8[b](#jcmm13711-note-0003){ref-type="fn"}   120.8[b](#jcmm13711-note-0003){ref-type="fn"}    135
  Crow                                                2018    T2DM         Without DM        America          American     51.1                                             35.5                                             117                                           52.4                                            32.9                                             117

DM, diabetes mellitus; SD, standard deviation; N, number; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; NIDDM, non‐independent diabetes mellitus; GDM, gestational diabetes mellitus.

The unit of paraoxonase 1 activity is nmol/min/mL.

Means calculated data from articles.

The unit of paraoxonase 1 activity is U/mL.

John Wiley & Sons, Ltd

###### 

Characteristics of studies included in this meta‐analysis for the relationship between paraoxon activity and risk of diabetes complications

  Author      Year    Type of DM   Country    Ethnicity    DM without complications                        DM with macroangiopathy                         DM with microangiopathy                                                                                                                                                                                                       
  ----------- ------- ------------ ---------- ------------ ----------------------------------------------- ----------------------------------------------- ------------------------- --------------------------------------------- ----------------------------------------------- ----- ----------------------------------------------- ----------------------------------------------- -----
  Mackness    2000    T2DM         English    Englishman   164.1[b](#jcmm13711-note-0007){ref-type="fn"}   76.63[b](#jcmm13711-note-0007){ref-type="fn"}   93                                                                                                                            113.4[b](#jcmm13711-note-0007){ref-type="fn"}   68.6[b](#jcmm13711-note-0007){ref-type="fn"}    101
  Letellier   2002    T2DM         France     French       207[b](#jcmm13711-note-0007){ref-type="fn"}     132[b](#jcmm13711-note-0007){ref-type="fn"}     96                        211[b](#jcmm13711-note-0007){ref-type="fn"}   189[b](#jcmm13711-note-0007){ref-type="fn"}     36    254[b](#jcmm13711-note-0007){ref-type="fn"}     155[b](#jcmm13711-note-0007){ref-type="fn"}     35
  Abdin       2010    T2DM         Egypt      Egyptian     23.33                                           11.93                                           20                                                                                                                            14.25                                           6.13                                            20
  Nowak       2010    T1DM         Poland     Polish       289.87                                          157.07                                          35                                                                                                                            227.66                                          123.57                                          41
  Poh         2010    T2DM         Malaysia   Malaysian    583                                             342                                             44                        442                                           244                                             96                                                                                                    
  Liu         2011    T2DM         China      Chinese      152                                             67                                              50                        110                                           46                                              50                                                                                                    
  Guo         2012    T2DM         China      Chinese      125.14                                          34.22                                           29                        94.49                                         28.87                                           37    93.26                                           26.81                                           42
  Gupta       2012    T2DM         Turkey     Turk         114.2[b](#jcmm13711-note-0007){ref-type="fn"}   47.42[b](#jcmm13711-note-0007){ref-type="fn"}   250                       51[b](#jcmm13711-note-0007){ref-type="fn"}    15.75[b](#jcmm13711-note-0007){ref-type="fn"}   300                                                                                                   
  Bansal      2013A   T2DM         India      Indian       276[b](#jcmm13711-note-0007){ref-type="fn"}     49.75[b](#jcmm13711-note-0007){ref-type="fn"}   57                        198[b](#jcmm13711-note-0007){ref-type="fn"}   35[b](#jcmm13711-note-0007){ref-type="fn"}      47    204                                             37.75[b](#jcmm13711-note-0007){ref-type="fn"}   53
  Bansal      2013B   T2DM         India      Indian       246[b](#jcmm13711-note-0007){ref-type="fn"}     40.33[b](#jcmm13711-note-0007){ref-type="fn"}   135                       172[b](#jcmm13711-note-0007){ref-type="fn"}   30.17[b](#jcmm13711-note-0007){ref-type="fn"}   130                                                                                                   
  Budak       2013    T2DM         Turkey     Turk         221                                             52                                              29                                                                                                                            199                                             39                                              25
  Sun         2017    DM           China      Chinese      352                                             184                                             10                        299                                           96                                              41                                                                                                    

DM, diabetes mellitus; SD, standard deviation; N, number; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus.

The unit of paraoxonase 1 activity is nmol/min/mL.

Means calculated data from articles.

John Wiley & Sons, Ltd

3.2. Paraoxonase 1 activity and DM risk {#jcmm13711-sec-0008}
---------------------------------------

As shown in Table [1](#jcmm13711-tbl-0001){ref-type="table"}, thirty‐four articles studied the association between paraoxonase 1 activity and risk of DM included 3474 DM patients and 3246 controls. Twenty‐one studies were performed in Asian countries,[10](#jcmm13711-bib-0010){ref-type="ref"}, [17](#jcmm13711-bib-0017){ref-type="ref"}, [18](#jcmm13711-bib-0018){ref-type="ref"}, [19](#jcmm13711-bib-0019){ref-type="ref"}, [20](#jcmm13711-bib-0020){ref-type="ref"}, [21](#jcmm13711-bib-0021){ref-type="ref"}, [22](#jcmm13711-bib-0022){ref-type="ref"}, [23](#jcmm13711-bib-0023){ref-type="ref"}, [24](#jcmm13711-bib-0024){ref-type="ref"}, [25](#jcmm13711-bib-0025){ref-type="ref"}, [26](#jcmm13711-bib-0026){ref-type="ref"}, [27](#jcmm13711-bib-0027){ref-type="ref"}, [28](#jcmm13711-bib-0028){ref-type="ref"}, [29](#jcmm13711-bib-0029){ref-type="ref"}, [30](#jcmm13711-bib-0030){ref-type="ref"}, [31](#jcmm13711-bib-0031){ref-type="ref"}, [32](#jcmm13711-bib-0032){ref-type="ref"}, [33](#jcmm13711-bib-0033){ref-type="ref"}, [34](#jcmm13711-bib-0034){ref-type="ref"}, [42](#jcmm13711-bib-0042){ref-type="ref"}, [43](#jcmm13711-bib-0043){ref-type="ref"} and other thirteen in non‐Asian.[9](#jcmm13711-bib-0009){ref-type="ref"}, [11](#jcmm13711-bib-0011){ref-type="ref"}, [12](#jcmm13711-bib-0012){ref-type="ref"}, [13](#jcmm13711-bib-0013){ref-type="ref"}, [14](#jcmm13711-bib-0014){ref-type="ref"}, [16](#jcmm13711-bib-0016){ref-type="ref"}, [35](#jcmm13711-bib-0035){ref-type="ref"}, [36](#jcmm13711-bib-0036){ref-type="ref"}, [37](#jcmm13711-bib-0037){ref-type="ref"}, [38](#jcmm13711-bib-0038){ref-type="ref"}, [39](#jcmm13711-bib-0039){ref-type="ref"}, [40](#jcmm13711-bib-0040){ref-type="ref"}, [41](#jcmm13711-bib-0041){ref-type="ref"} Twenty‐three articles were focused on T2DM, one on T1DM and T2DM,[37](#jcmm13711-bib-0037){ref-type="ref"} four on TDM,[13](#jcmm13711-bib-0013){ref-type="ref"}, [16](#jcmm13711-bib-0016){ref-type="ref"}, [38](#jcmm13711-bib-0038){ref-type="ref"}, [41](#jcmm13711-bib-0041){ref-type="ref"} two on GDM[26](#jcmm13711-bib-0026){ref-type="ref"}, [40](#jcmm13711-bib-0040){ref-type="ref"} or one on NIDDM,[20](#jcmm13711-bib-0020){ref-type="ref"} and three[12](#jcmm13711-bib-0012){ref-type="ref"}, [32](#jcmm13711-bib-0032){ref-type="ref"}, [34](#jcmm13711-bib-0034){ref-type="ref"} were unknown. The result showed significant heterogeneity was found (*I* ^2^ = 98.10%, *P *=* *.000, Figure [2](#jcmm13711-fig-0002){ref-type="fig"}). Therefore, we performed subgroup analyses on ethnicity (categorized as Asian and non‐Asian groups), type of DM (categorized as T2DM, T1DM and other DMs) and type of control (categorized as healthy control and without DM) to investigate the sources of heterogeneity. However, significant heterogeneities were still existed in each subgroup (data not shown). Therefore, meta‐regression was used to identify the sources of this heterogeneity, using the following covariates: published year, sample size, ethnicity, type of control and type of DM. The results showed that ethnicity could explain the observed between‐study heterogeneity (*P *=* *.002, Table [3](#jcmm13711-tbl-0003){ref-type="table"}).

![Forest plot for the association between paraoxonase 1 activity with DM, subgrouped by type of diabetes mellitus](JCMM-22-4283-g002){#jcmm13711-fig-0002}

###### 

The meta‐regression results for the association between paraoxonase activity and susceptibility of diabetes mellitus

  Covariates                  Coefficient   Standard error   *Z* value   *P* value                                      95% confidence interval
  --------------------------- ------------- ---------------- ----------- ---------------------------------------------- -------------------------
  Published year              −0.0329444    0.0581352        −0.57       .571                                           −0.1468872˜0.0809985
  Sample size                 0.0022293     0.0018531        1.20        .229                                           −0.0014027˜0.0058613
  Ethnicity                   −1.465915     0.4797128        −3.06       .002[a](#jcmm13711-note-0008){ref-type="fn"}   −2.406135˜−0.5256954
  Type of control             −0.139538     1.085985         −0.13       .898                                           −2.268029˜1.988953
  Type of diabetes mellitus   0.2003757     0.3617462        0.55        .580                                           −0.5086338˜0.9093852

*P *\<* *.05.

John Wiley & Sons, Ltd

Meta‐analysis showed significant relationship between paraoxonase 1 activity and susceptibility of DM (SMD = −1.37, 95% CI = −1.79 ∼ −0.96, *P *=* *.000, Figure [2](#jcmm13711-fig-0002){ref-type="fig"}). Risk of DM obviously increased with low levels of paraoxonase 1 activity. Subgroup analysis on type of DM showed significant relationships found in T2DM subgroup (SMD = −1.54, 95% CI = −2.10 ∼ −0.98, *P *=* *.000), T1DM subgroup (SMD = −0.55, 95% CI = −1.03 ∼ −0.08, *P *=* *.023) and other types of DM (SMD = −1.26, 95% CI = −2.00 to −0.52, *P *=* *.001) (Figure [2](#jcmm13711-fig-0002){ref-type="fig"}). Meanwhile, the result of subgroup analysis on ethnicity showed significant associations between paraoxonase 1 activity and DM in Asian group (SMD = −2.00, 95% CI = −2.56 ∼ −1.44, *P *=* *.000, Supporting information Figure [S1](#jcmm13711-sup-0001){ref-type="supplementary-material"}), but not in non‐Asian group (SMD = −0.44, 95% CI = −0.91 ∼ 0.03, *P *=* *.069, Supporting information Figure [S1](#jcmm13711-sup-0001){ref-type="supplementary-material"}). Significant publication bias was found using funnel plot and Egger\'s test (*P *=* *.008, data not shown).

3.3. Paraoxonase 1 activity and susceptibility of diabetic macroangiopathy {#jcmm13711-sec-0009}
--------------------------------------------------------------------------

As shown in Table [2](#jcmm13711-tbl-0002){ref-type="table"}, eight articles focused on the association of paraoxonase 1 activity and the risk of diabetic macroangiopathy, including 737 cases and 671 controls.[17](#jcmm13711-bib-0017){ref-type="ref"}, [18](#jcmm13711-bib-0018){ref-type="ref"}, [22](#jcmm13711-bib-0022){ref-type="ref"}, [30](#jcmm13711-bib-0030){ref-type="ref"}, [31](#jcmm13711-bib-0031){ref-type="ref"}, [34](#jcmm13711-bib-0034){ref-type="ref"}, [35](#jcmm13711-bib-0035){ref-type="ref"}, [44](#jcmm13711-bib-0044){ref-type="ref"} The results showed that significant heterogeneity was found (*I* ^2^ = 94.90%, *P *=* *.000, Figure [3](#jcmm13711-fig-0003){ref-type="fig"}A). Paraoxonase 1 activity was significantly associated with the susceptibility of diabetic macroangiopathy (SMD = −1.06, 95% CI = −1.63 ∼ −0.48, *P *=* *.000, Figure [3](#jcmm13711-fig-0003){ref-type="fig"}A). There was no significant publication bias existed, demonstrated by funnel plot and Egger\'s test (*P *=* *.116, data not shown).

![A, Forest plot for the association between paraoxonase 1 activity with diabetic macroangiopathy; B, Forest plot for the association between paraoxonase 1 activity with diabetic microangiopathy](JCMM-22-4283-g003){#jcmm13711-fig-0003}

3.4. Paraoxonase 1 activity and susceptibility of diabetic microangiopathy {#jcmm13711-sec-0010}
--------------------------------------------------------------------------

As shown in Table [2](#jcmm13711-tbl-0002){ref-type="table"}, seven articles focused on the association of paraoxonase 1 activity and the risk of diabetic microangiopathy, including 317 cases and 359 controls.[15](#jcmm13711-bib-0015){ref-type="ref"}, [17](#jcmm13711-bib-0017){ref-type="ref"}, [23](#jcmm13711-bib-0023){ref-type="ref"}, [31](#jcmm13711-bib-0031){ref-type="ref"}, [35](#jcmm13711-bib-0035){ref-type="ref"}, [38](#jcmm13711-bib-0038){ref-type="ref"}, [43](#jcmm13711-bib-0043){ref-type="ref"} The results showed that significant heterogeneity was found (*I* ^2^ = 92.0%, *P *=* *.000, Figure [3](#jcmm13711-fig-0003){ref-type="fig"}B). Paraoxonase 1 activity was significantly associated with the susceptibility of diabetic microangiopathy (SMD = −0.72, 95% CI = −1.32 ∼ −0.13, *P *=* *.018, Figure [3](#jcmm13711-fig-0003){ref-type="fig"}B). Meanwhile, there was no significant publication bias, according to funnel plot and Egger\'s test (*P *=* *.533, data not shown).

4. DISCUSSION {#jcmm13711-sec-0011}
=============

Our meta‐analysis firstly demonstrated the associations between paraoxonase 1 activity and DM, diabetic macroangiopathy and diabetic microangiopathy by polling the individual data set. In the overall meta‐analysis of paraoxonase 1 activity, susceptibility of DM significantly increased with low levels of paraoxonase 1 activity, but strong between‐study heterogeneity was found. Therefore, to address the substantial heterogeneity, subgroup analyses on ethnicity, type of control and type of DM were conducted. But significant heterogeneity was still existed. Then, meta‐regression was performed using the following covariates: published year, sample size, ethnicity, type of control and type of DM and the results showed that ethnicity could explain the observed between‐study heterogeneity. In addition, subgroup analysis showed significant associations between paraoxonase 1 activity and DM in Asian group, but not in non‐Asian group. Paraoxonase 1 activity was different from ethnicity, and significantly higher in Malays and Chinese than Indians.[22](#jcmm13711-bib-0022){ref-type="ref"} A recent meta‐analysis on the associations of paraoxonase 1 Q192R/L55M genetic polymorphisms with susceptibility of T2DM also suggested a significant ethnicity differences.[5](#jcmm13711-bib-0005){ref-type="ref"} There are huge racial and regional differences in the genetic polymorphisms of paraoxonase 1, according to the 1000 genomes database.[5](#jcmm13711-bib-0005){ref-type="ref"} Genetic polymorphisms of paraoxonase 1 have been demonstrated to affect the paraoxonase 1 activity.[45](#jcmm13711-bib-0045){ref-type="ref"} Regarding the paraoxonase 1 Q192R polymorphism, paraoxonase 1 activity was different from genotypes, with the highest level in genotype RR in an Egyptian population,[42](#jcmm13711-bib-0042){ref-type="ref"} and the lowest level in genotype QQ in an African population.[46](#jcmm13711-bib-0046){ref-type="ref"} Paraoxonase 1 activity was significantly lower in the genotype QQ of paraoxonase 1 Q192R polymorphism than genotypes QR and RR in the patients with diabetic macroangiopathy.[42](#jcmm13711-bib-0042){ref-type="ref"} Meanwhile, paraoxonase 1 activity was significantly lower in the genotype LL of the paraoxonase 1 L55M polymorphism than genotypes LM and MM in the patients with diabetic macroangiopathy and microangiopathy in an Egyptian population, while no difference between L and M alleles.[42](#jcmm13711-bib-0042){ref-type="ref"} So the effect of interaction between paraoxonase 1 activity and genetic polymorphisms on the susceptibility of DM regarding the ethnic difference needs to be studied in the further.

Diabetic macroangiopathy is one of the most common complications of DM, which reduced the mortality and life quality of DM patients. It is a specific type of accelerated atherosclerosis. In this meta‐analysis, paraoxonase 1 activity was significantly associated with the susceptibility of diabetic macroangiopathy. Diabetic microangiopathy including diabetic nephropathy and diabetic retinopathy is also one of the most common complications. Diabetic nephropathy is the leading global cause of end‐stage renal disease. In this meta‐analysis, paraoxonase 1 activity was significantly associated with the susceptibility of diabetic microangiopathy.

Paraoxonase 1 can cleave oxidized lipids from low‐density lipoproteins. High‐density lipoproteins diminish the accumulation of lipid peroxides in low‐density lipoproteins mainly due to paraoxonase 1 activity. Paraoxonase 1 activity in human beings is very low at birth and increases with time.[47](#jcmm13711-bib-0047){ref-type="ref"} As our meta‐analysis has demonstrated the significant role of paraoxonase 1 activity in DM and diabetic complications, therapeutic strategies targeting this enzyme maybe reasonable. Therapeutic strategies can be focused on lifestyle modification and increasing the level of paraoxonase 1 activity.

In this meta‐analysis, there existed some limitations. First, only articles with English and Chinese language were included in this study, some publication bias may exist. Second, significant heterogeneity was found in our analysis about the association between paraoxonase 1 activity and susceptibility of DM and diabetic complications, and for DM, ethnicity might explain some of the sources of between‐study heterogeneity. But there were only 8 and 7 articles included for analysis of the association between paraoxonase 1 activity and diabetic macroangiopathy and microangiopathy, respectively, so we failed to find the sources of heterogeneity. Thus, large sample and well‐designed studies needed to demonstrate the result in the further.

In conclusion, paraoxonase 1 activity plays important roles in the risk of DM, diabetic macroangiopathy and microangiopathy with ethnicity differences. Further studies with large sample and well design are needed to confirm these results.
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